NOBIVAC LYME - Safety

By: Intervet  09-12-2011
Keywords: Dogs

The safety of Nobivac® Lyme in dogs 8 weeks or older was confirmed in a 618-dog field study.1

Client-owned dogs were vaccinated subcutaneously with a 1-mL dose of Nobivac® Lyme and boosted with an additional 1-mL dose 21 days later, for a total of 1,236 vaccine administrations. Dogs were monitored for adverse reactions beginning with the first vaccination and continuing through 14 days after the second vaccination.

Subcutaneous administration of Nobivac® Lyme was infrequently associated with pain on injection and had a low incidence of localized reactions. Mild, transient soft tissue swelling, which may occur at the injection site, is a typical response following subcutaneous vaccination with a whole-cell bacterin. Overall, less than 1% of dogs experienced adverse reactions attributable to the vaccine.

  • The vaccine was well-tolerated on subcutaneous administration
  • Nobivac® Lyme was 99.3% reaction-free
  • No dogs were removed from the study
Reference:

1. Data on file at Intervet/Schering-Plough Animal Health.

Keywords: Dogs

Contact Intervet

Email - none provided

Print this page

Other products and services from Intervet

09-12-2011

NOBIVAC LYME - Efficacy

LaFleur RL, Dant JC, Wasmoen TL, et al. Bacterin that induces anti-OspA and anti-OspC borreliacidal antibodies provides a high level of protection against canine Lyme disease. 15 vaccinates and 15 controls received either Nobivac® Lyme or a placebo injection administered subcutaneously on Days 0 and 21. Nobivac® Lyme has been shown to produce borreliacidal antibodies that are highly effective in killing Borrelia burgdorferi.1.


09-12-2011

NOBIVAC LYME - Overview

Nobivac® Lyme is a bacterin that contains two inactivated strains of Borrelia burgdorferi comprised of outer surface protein A and outer surface protein C. This bacterin is approved for the vaccination of healthy dogs as an aid in the prevention of subclinical arthritis caused by B. burgdorferi. Lyme is administered subcutaneously as an initial vaccination followed by a booster 2 to 4 weeks later.


09-12-2011

NOBIVAC LYME - Lyme Disease Transmission

Soon after the tick takes its bloodmeal, OspA expression decreases and OspC expression increases, becoming the dominant outer surface protein. When a Borrelia-infected tick attaches to a dog, high levels of OspA are expressed by the Borrelia, which are residing in the tick’s midgut. Burgdorferi have different outer surface proteins that act as antigens and are expressed at various phases in the tick feeding cycle.


09-12-2011

NOBIVAC LYME - Mechanism of Action

Nobivac® Lyme was specifically designed to target two key factors involved in the transmission of Lyme disease—OspA and OspC.1. OspC borreliacidal antibodies can kill Borrelia in the tick and in the dog. OspA borreliacidal antibodies can only kill Borrelia in the feeding tick. Nobivac® Lyme combines 2 isolates of Borrelia burgdorferi.